title: A review of the gastrointestinal therapeutic system (GITS) formulation and its effectiveness in the delivery of antihypertensive drug treatment (focus on nifedipine GITS).
abstract: Hypertension treatment guidelines do not discriminate within drug classes and, furthermore, do not consider whether or not all of the formulations of any given drug licensed for once-daily administration can be considered to be therapeutically interchangeable. This article focuses on this issue with respect to nifedipine and the development of the gastrointestinal therapeutic system (GITS) formulation. Nifedipine GITS is regarded as the gold standard once-daily formulation of nifedipine and, as such, it is anticipated that alternative formulations will be therapeutically equivalent to nifedipine GITS. In general, this depends on demonstrating pharmacokinetic bioequivalence. This article is intended to focus attention on generic substitution and, in particular, on aspects of the scientific basis for the substitution of generic products in place of branded products. Such substitution is required for cost-saving or cost-containment reasons and is justified on the basis that the generic (substitute) drug is "therapeutically" equivalent to the branded drug. Unfortunately, there are serious shortcomings in the current methods of assessment insofar as they are typically based on statistical comparisons of average pharmacokinetic parameter values, using arbitrary comparative criteria. This article illustrates the shortcomings of the current approaches to generic substitution and concludes that, in regulatory terms, either more rigorous pharmacokinetic criteria are required or pharmacodynamic indices should be added to reinforce the regulatory criteria. Generic substitution is a balancing act but, at the moment, the cost issue is dominant. To restore the balance, equivalent efficacy must be confirmed. At present, therefore, in the absence of such regulatory rigor, the obvious course is to prefer the branded product, the therapeutic efficacy of which (including outcome benefits) has been established.
authors.affiliation: Medicine and Therapeutics, University of Glasgow, The Western Infirmary, Glasgow, United Kingdom.
authors.forename: Peter A
authors.initials: PA
authors.lastname: Meredith
authors.forename: Henry L
authors.initials: HL
authors.lastname: Elliott
keywords: bioequivalence; cardiovascular outcome; generic; generic substitution; nifedipine GITS; safety
references.citation: Int J Clin Pharmacol Ther. 2010 Feb;48(2):158-70
references.pmid: 20137768
references.citation: Clin Ther. 2003 Nov;25(11):2875-90
references.pmid: 14693311
references.citation: Br J Clin Pharmacol. 2002 Jun;53(6):582-8
references.pmid: 12047482
references.citation: J Hypertens. 2003 Nov;21(11):1983-92
references.pmid: 14597836
references.citation: Drug Dev Ind Pharm. 2000 Jul;26(7):695-708
references.pmid: 10872087
references.citation: Am J Health Syst Pharm. 1998 Apr 1;55(7):686-7
references.pmid: 9558425
references.citation: J Control Release. 1998 Mar 31;52(3):301-10
references.pmid: 9743450
references.citation: J Hum Hypertens. 2002 Mar;16 Suppl 1:S151-5
references.pmid: 11986915
references.citation: Clin Pharmacokinet. 1992 Jun;22(6):416-33
references.pmid: 1587055
references.citation: J Hum Hypertens. 2002 Mar;16 Suppl 1:S156-60
references.pmid: 11986916
references.citation: Eur J Pharm Sci. 2002 Apr;15(3):279-85
references.pmid: 11923060
references.citation: J Hypertens. 2004 Sep;22(9):1641-8
references.pmid: 15311086
references.citation: Am J Med. 1989 Aug 16;87(2A):31S-35S
references.pmid: 2764016
references.citation: Br J Clin Pharmacol. 2008 May;65(5):646-52
references.pmid: 18093252
references.citation: Int J Clin Pharmacol Ther. 2006 Jan;44(1):38-48
references.pmid: 16425970
references.citation: Int J Clin Pharmacol Ther. 2010 Jun;48(6):400-4
references.pmid: 20497748
references.citation: J Hypertens. 2007 Jun;25(6):1105-87
references.pmid: 17563527
references.citation: Drugs. 2006;66(4):497-528
references.pmid: 16597165
references.citation: Drug Deliv. 2008 Jan;15(1):43-8
references.pmid: 18197523
references.citation: J Cardiovasc Pharmacol. 1987;10 Suppl 10:S76-8
references.pmid: 2455148
references.citation: BMJ. 2009 May 19;338:b1665
references.pmid: 19454737
references.citation: Am J Med. 1987 Dec 21;83(6B):3-9
references.pmid: 3503595
references.citation: Vasc Health Risk Manag. 2009;5(1):429-40
references.pmid: 19475779
references.citation: Hypertension. 2003 Dec;42(6):1206-52
references.pmid: 14656957
references.citation: Lancet. 2002 Dec 14;360(9349):1903-13
references.pmid: 12493255
references.citation: Eur J Clin Pharmacol. 2002 May;58(2):119-25
references.pmid: 12012144
references.citation: Curr Med Res Opin. 2006 Oct;22(10):1879-92
references.pmid: 17022845
references.citation: Hypertension. 1988 Oct;12(4):443-9
references.pmid: 3169952
references.citation: Lancet. 2000 Jul 29;356(9227):366-72
references.pmid: 10972368
references.citation: Am J Cardiol. 1997 Dec 1;80(11):1453-8
references.pmid: 9399721
references.citation: Lancet. 2004 Sep 4-10;364(9437):849-57
references.pmid: 15351192
references.citation: Circulation. 2003 Nov 25;108(21):2608-10
references.pmid: 14638524
references.citation: Clin Ther. 2008 Jan;30(1):48-58
references.pmid: 18343242
references.citation: Clin Pharmacol Ther. 1984 Jun;35(6):742-9
references.pmid: 6734025